Jacob Bleesing

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6516335/publications.pdf

Version: 2024-02-01

44	1,707	471371 17	377752 34
papers	citations	h-index	g-index

45	45	45	3011
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	T-follicular helper cell expansion and chronic T-cell activation are characteristic immune anomalies in Evans syndrome. Blood, 2022, 139, 369-383.	0.6	14
2	Human Papillomavirus Oral- and Sero- Positivity in Fanconi Anemia. Cancers, 2021, 13, 1368.	1.7	3
3	Successful liver transplantation in short telomere syndromes without bone marrow failure due to DKC1 mutation. Pediatric Transplantation, 2020, 24, e13695.	0.5	8
4	Complement blockade for TA-TMA: lessons learned from large pediatric cohort treated with eculizumab. Blood, 2020, 135, 1049-1057.	0.6	103
5	Thinking Beyond HLH: Clinical Features of Patients with Concurrent Presentation of Hemophagocytic Lymphohistiocytosis and Thrombotic Microangiopathy. Journal of Clinical Immunology, 2020, 40, 699-707.	2.0	35
6	The Value of Chromosome Analysis to Interrogate Variants in DNMT3B Causing Immunodeficiency, Centromeric Instability, and Facial Anomaly Syndrome Type I (ICF1). Journal of Clinical Immunology, 2019, 39, 857-859.	2.0	5
7	Two Unique Cases of X-linked SCID: A Diagnostic Challenge in the Era of Newborn Screening. Frontiers in Pediatrics, 2019, 7, 55.	0.9	10
8	Loss of GTPase of immunity-associated protein 5 (Gimap5) promotes pathogenic CD4+ T-cell development and allergic airway disease. Journal of Allergy and Clinical Immunology, 2019, 143, 245-257.e6.	1.5	10
9	Enhanced Transduction Lentivector Gene Therapy for Treatment of Older Patients with X-Linked Severe Combined Immunodeficiency. Blood, 2019, 134, 608-608.	0.6	7
10	Partial RAG deficiency in a patient withÂvaricella infection, autoimmune cytopenia, and anticytokine antibodies. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 1769-1771.e2.	2.0	25
11	Gimap5-dependent inactivation of GSK3Î² is required for CD4+ T cell homeostasis and prevention of immune pathology. Nature Communications, 2018, 9, 430.	5.8	32
12	Outcome of hematopoietic cell transplantation for DNA double-strand break repair disorders. Journal of Allergy and Clinical Immunology, 2018, 141, 322-328.e10.	1.5	79
13	Hypogammaglobulinemia with decreased class-switched B-cells and dysregulated T-follicular-helper cells in IPEX syndrome. Clinical Immunology, 2018, 197, 219-223.	1.4	15
14	Screening for Wiskott-Aldrich syndrome by flow cytometry. Journal of Allergy and Clinical Immunology, 2018, 142, 333-335.e8.	1.5	20
15	Immune Reconstitution after Alemtuzumab, Fludarabine, and Melphalan Reduced Intensity Conditioning. Biology of Blood and Marrow Transplantation, 2017, 23, S163.	2.0	0
16	Incidence of Central Nervous System Hemophagocytic Lymphohistiocytosis Relapse after Reduced Intensity Conditioning Stem Cell Transplant in Children. Biology of Blood and Marrow Transplantation, 2017, 23, S240-S241.	2.0	0
17	Genotype, Phenotype and T Cell Counts at One Year Predict Survival and Long Term Immune Reconstitution after Transplantation in Severe Combined Immune Deficiency (SCID)â€"The Primary Immune Deficiency Treatment Consortium (PIDTC). Biology of Blood and Marrow Transplantation, 2017, 23, S133-S134.	2.0	4
18	Thrombotic Microangiopathy Can Occur Before Transplant in Children with HLH. Biology of Blood and Marrow Transplantation, 2017, 23, S233-S234.	2.0	2

#	Article	IF	Citations
19	Hematopoietic stem cell transplantation in 29 patients hemizygous for hypomorphic IKBKG/NEMO mutations. Blood, 2017, 130, 1456-1467.	0.6	95
20	Outcome of patients with NEMO deficiency following allogeneic hematopoietic cell transplant. Journal of Allergy and Clinical Immunology, 2017, 139, 1040-1043.e2.	1.5	13
21	Natural Killer Cells from Patients with Recombinase-Activating Gene and Non-Homologous End Joining Gene Defects Comprise a Higher Frequency of CD56bright NKG2A+++ Cells, and Yet Display Increased Degranulation and Higher Perforin Content. Frontiers in Immunology, 2017, 8, 798.	2.2	41
22	Phase 1 Study of Maraviroc As Acute Graft-Versus-Host Disease Prophylaxis in Pediatrics. Biology of Blood and Marrow Transplantation, 2016, 22, S96-S97.	2.0	0
23	Defects of B-cell terminal differentiation in patients with type-1 Kabuki syndrome. Journal of Allergy and Clinical Immunology, 2016, 137, 179-187.e10.	1.5	73
24	Prospective Pilot Study Evaluating Sleep Disruption in Children and Young Adults Undergoing Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, S216.	2.0	3
25	A Modified Î³-Retrovirus Vector for X-Linked Severe Combined Immunodeficiency. New England Journal of Medicine, 2014, 371, 1407-1417.	13.9	358
26	Bortezomib Is a Successful Therapeutic Agent for Refractory Autoimmune Cytopenias in Children: A Single Center Experience. Biology of Blood and Marrow Transplantation, 2014, 20, S174.	2.0	0
27	Differential role of nonhomologous end joining factors in the generation, DNA damage response, and myeloid differentiation of human induced pluripotent stem cells. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 8889-8894.	3.3	34
28	Reduced Intensity Hematopoietic Cell Transplantation for Non-Fanconi Anemia Marrow Failure Syndromes. Biology of Blood and Marrow Transplantation, 2013, 19, S252.	2.0	0
29	Alternate Day Micafungin Antifungal Prophylaxis in High Risk Pediatric Patients Undergoing Hematopoietic Cell Transplantation (HCT). Biology of Blood and Marrow Transplantation, 2013, 19, S260.	2.0	0
30	Case Series of Vaccine Associated Varicella Zoster Virus Infection in Immune Compromised Patients. Biology of Blood and Marrow Transplantation, 2013, 19, S250.	2.0	2
31	Preliminary Results From a Single Institutional Prospective Study of Alemtuzumab for the Treatment of Steroid Refractory Acute Graft Versus Host Disease in Pediatrics. Biology of Blood and Marrow Transplantation, 2013, 19, S331.	2.0	0
32	The Schedule and Dose of Alemtuzumab Determine the Incidence of Mixed Chimerism in Pediatric Patients Undergoing Reduced Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2013, 19, S123.	2.0	2
33	The Outcome of Allogeneic Hematopoietic Stem Cell Transplantation Following Liver Transplantation in Children with Immunodeficiencies. Biology of Blood and Marrow Transplantation, 2013, 19, S296.	2.0	0
34	A Novel Intermediate Alemtuzumab Schedule Optimizes the Incidences of Mixed Chimerism and Acute GVHD in Patients with HLH and XLP Undergoing Allogeneic HCT. Biology of Blood and Marrow Transplantation, 2013, 19, S298.	2.0	0
35	Adolescents and Young Adults With Hemophagocytic Lymphohistiocytosis Who Undergo Allogeneic Hematopoietic Cell Transplantation Are At Increased Risk Of Mortality Compared To Younger Patients. Blood, 2013, 122, 2087-2087.	0.6	3
36	A Unique Clinical Presentation of X-Linked Lymphoproliferative Syndrome With a Novel Mutation in SH2D1A and Review of the Literature. Journal of Pediatric Hematology/Oncology, 2011, 33, e39-e42.	0.3	1

#	Article	IF	Citations
37	Use of intravenous immunoglobulin and adjunctive therapies in the treatment of primary immunodeficiencies. Clinical Immunology, 2010, 135, 255-263.	1.4	86
38	Expansion of immunoglobulin-secreting cells and defects in B cell tolerance in Rag-dependent immunodeficiency. Journal of Experimental Medicine, 2010, 207, 1541-1554.	4.2	90
39	Alternate-Day Micafungin Antifungal Prophylaxis in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation: A Pharmacokinetic Study. Biology of Blood and Marrow Transplantation, 2010, 16, 1458-1462.	2.0	40
40	Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome. British Journal of Haematology, 2009, 145, 101-106.	1.2	151
41	ADOLESCENT PRESENTATION OF X-LINKED LYMPHOPROLIFERATIVE DISEASE. Annals of Allergy, Asthma and Immunology, 2008, 100, 398-400.	0.5	0
42	Complete Responses in Patients with Autoimmune Lymphoproliferative Syndrome (ALPS) Using the mTOR Inhibitor Sirolimus (rapamycin). Blood, 2008, 112, 2569-2569.	0.6	0
43	The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor Î±-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis. Arthritis and Rheumatism, 2007, 56, 965-971.	6.7	294
44	Autoimmune Lymphoproliferative Syndrome (ALPS). Current Pharmaceutical Design, 2003, 9, 265-278.	0.9	37